Acute profound thrombocytopenia associated with readministration of eptifibatide: Case report and review of the literature

Pharmacotherapy

Volumn 29, Issue 7, 2009, Pages 867-874

  Russell, Kimberly N ^a,b   Schnabel, Joseph G ^c   Rochetto, Richard P ^c   Tanner, Matthew C ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b Southwest Washington Medical Center   (United States)

^c Salem Hospital   (United States)

Author keywords

Eptifibatide; Glycoprotein IIb IIIa inhibitor; Platelet count; Thrombocytopenia

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ARGATROBAN; BICARBONATE; CIPROFLOXACIN; CLOPIDOGREL; DEXAMETHASONE; EPTIFIBATIDE; GLYCERYL TRINITRATE; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; INSULIN; ISOSORBIDE MONONITRATE; LORAZEPAM; METOCLOPRAMIDE; METOPROLOL; MEVINOLIN; MORPHINE; NICOTINE PATCH; ONDANSETRON; OXYCODONE; PROTAMINE SULFATE; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ACUTE PROFOUND THROMBOCYTOPENIA; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERYTHROCYTE CONCENTRATE; FEMALE; FRACTURE; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSULIN DEPENDENT DIABETES MELLITUS; KNEE AMPUTATION; LABORATORY TEST; LUNG EMBOLISM; OVARY CANCER; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PETECHIA; PURPURA; SCORING SYSTEM; SMOKING; STENT; STOMACH CANCER; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRAFFIC ACCIDENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ACUTE DISEASE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA;

EID: 67650786283     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.7.867     Document Type: Article

References (31)

1. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;97:2386-2395
2. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356: 2037-2044 (Erratum in Lancet 2001;357:1370.)
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Drug information page. Integrilin (eptifibatide) injection. Available from http://www.fda.gov/ Cder/foi/nda/98/20718-Integrilin.htm. Accessed June 5, 2008.
4. Hongo RH, Nrent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 2001;88:428-431 (Pubitemid 32823310)
5. Yoder M, Edwards RF. Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 2002;36:628-630
6. Nagge J, Jackevicus C, Dzavik V, Ross JR, Seidelin P. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003;23:374-379 (Pubitemid 36259342)
7. Tanaka KA, Vega JD, Kelly B, Hanson SR, Levy JH. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 2003;1:392-394
8. Morel O, Jesel L, Chauvin M, Freyssinet JM, Toti F. Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost 2003;1:2685-2687
9. Rezkalla SH, Hayes JJ, Curtis BR, Aster RH. Eptifibatideinduced acute profound thrombocytopenia presenting as refractory hypotension. Cathet Cardiovasc Intervent 2003;58:76-79 (Pubitemid 36055306)
10. Salengro E, Mulvihill NT, Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Cathet Cardiovasc Intervent 2003;58:73-75 (Pubitemid 36055305)
11. Coons JC, Barcelona RA, Freedy T, Hagerty MF. Eptifibatideassociated acute, profound thrombocytopenia. Ann Pharmacother 2005;39:368-372
12. Cheema AA, Teklinski AH, Maria V, Chilukuri K, Frank JJ, Gosselin MO. Recurrent acute profound thrombocytopenia related to readministration of eptifibatide. J Intervent Cardiol 2006;19:99-103.
13. Epelman S, Nair D, Downey R, Militello M, Askari AT. Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis 2006;22:151-154
14. Paradiso-Hardy FL, Madan M, Radhakrishnan S, Hurden S, Cohen EA. Severe thrombocytopenia possibly related to readministration of eptifibatide. Cathet Cardiovasc Intervent 2001;54:63-67 (Pubitemid 32851992)
15. Khaykin Y, Paradiso-Hardy FL, Madan M. Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol 2003;19:797-801. (Pubitemid 36992485)
16. Onitilo AA. Delayed profound thrombocytopenia associated with eptifibatide. Am J Hematol 2006;81:984-988 (Pubitemid 44864461)
17. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813 (Pubitemid 27091518)
18. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
19. McCrae KR, Herman JH. Posttransfusion purpura: two unusual cases and a literature review. Am J Hematol 1996;52:205-211 (Pubitemid 26254858)
20. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133(6 suppl):S340-80. (Pubitemid 351892970)
21. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007;27:564-587 (Pubitemid 46536238)
22. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
23. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004:126(3 suppl):S311-37. (Erratum in Chest 2005; 127:416.) (Pubitemid 39297959)
24. Marraffa J, Guharoy R, Duggan D, Rose F, Nazeer S. Vancomycin-induced thrombocytopenia: a case proven with rechallenge. Pharmacotherapy 2003:23:1195-1198 (Pubitemid 37158788)
25. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycininduced immune thrombocytopenia. N Engl J Med 2007;356: 904-910
26. Howard CE, Adams LA, Admire JL, Chu MA, Alred GL. Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Ann Pharmacother 1997;31:315-318
27. Bristol-Myers Squibb-Sanofi Pharmaceuticals Partnership. Plavix (clopidogrel) package insert. Bridgewater, NJ; 2007.
28. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenia purpura. J Am Coll Cardiol 2007;50: 1138-1148
29. Manor SM, Guillory GS, Jain SP. Clopidogrel-induced thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy 2004;24:664-667 (Pubitemid 38585961)
30. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005;127:S53-9. (Pubitemid 40224082)
31. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076 (Pubitemid 35001239)